FindTrial
Sign In

NEO100

DRUG2 trials

Sponsors

Neonc Technologies, Inc.

Conditions

Choroid Plexus Carcinoma, ChildhoodDiffuse Midline Glioma, H3 K27M-MutantHigh Grade GliomaPediatric Tumor of BrainPediatric Tumor of Brain StemPediatric Tumor of CNSPineocytomaResidual, Progressive or Recurrent Grade II or III Meningioma

Phase 1

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
RecruitingNCT06357377
Neonc Technologies, Inc.Choroid Plexus Carcinoma, Childhood, Diffuse Midline Glioma, H3 K27M-Mutant, High Grade Glioma +5
Start: 2026-09-08End: 2027-07-01Target: 12Updated: 2026-09-15

Phase 2

NEO100 and High-Grade Meningioma
RecruitingNCT05023018
Neonc Technologies, Inc.Residual, Progressive or Recurrent Grade II or III Meningioma
Start: 2022-07-01End: 2027-06-30Target: 30Updated: 2026-09-15